Evaxion to Present Phase 2 EVX-01 Biomarker Data at SITC 2026
Evaxion says it will present new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting.
Evaxion says it will present new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting.